Abstract:Objective: To analyze the efficacy of wet age-related macular degeneration (wAMD) in combination with ranibizumab (IVR) injection and modified Zhujing formula. Methods: The research subjects were 60 patients with wAMD in the ophthalmology department of Yulin Hospital of Traditional Chinese Medicine from September 2022 to October 2024. The research subjects were divided into the experimental group and the control group according to the random number table method. The control group (n=30) was treated with IVR, while the experimental group (n=30) was treated with modified Zujingfang on the basis of IVR injection. The clinical efficacy, TCM symptom scores, central retinal thickness (CRT), best corrected visual acuity (BCVA), macular hemorrhage area, choroidal neovascularization area (CNV), ocular hemodynamic parameters [resistance index (RI), maximum diastolic blood flow (EDV), maximum systolic blood flow (PSV)], and 1-year recurrence rate were compared between the two groups. Results: The clinical efficacy of the experimental group (96.67%) was higher than that of the control group (76.67%) (P<0.05). After treatment, the scores of blurred vision, soreness and weakness of the waist and knees, restlessness and insomnia, dizziness and tinnitus in the experimental group were all lower than those in the control group (P<0.05). After treatment, the EDV and PSV in the experimental group were both higher than those in the control group (P<0.05). After treatment, the BCVA, CRT, macular hemorrhage area, CNV and RI of the experimental group were all lower than those of the control group (P<0.05), and the 1-year recurrence rate in the experimental group (3.33%) was lower than that in the control group (26.67%) (P<0.05). Conclusion: The modified Zujingfang combined with ranibizumab can effectively alleviate symptoms such as blurred vision and fundus hemorrhage in patients with wAMD, improve visual acuity and ocular hemodynamics, and reduce the recurrence rate, with remarkable effects.
